Pioneering Science
The tau tangle pathway is a key driver of Alzheimer’s disease leading to loss of neuronal function, spread of pathology and clinical symptoms. View
The tau tangle pathway is a key driver of Alzheimer’s disease leading to loss of neuronal function, spread of pathology and clinical symptoms. View
TauRx’s tau aggregation inhibitors are the outcome of nearly 30 years of research, preclinical and clinical investigations. View
LUCIDITY, a new clinical trial examining the effects of LMTX® in patients with mild Alzheimer’s disease, is now underway. View
Claude Wischik, TauRx CEO, discusses the clinical development of LMTX, and what the recent Phase 3 results mean for TauRx’s on-going development programme.
Claude Wischik explores TauRx’s broad-based research activities including its pioneering work on both the treatment and early diagnosis of AD.
Claude Wischik talks about how the Alzheimer’s research landscape has evolved over the past thirty years and the impact of the disease on patients and their families.